Sarah G. Brooks

Sarah G. Brooks

Auto-generated profile, based on publicly available information

Sarah G. Brooks

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, Miller School of Medicine, University of Miami, Miami, Florida, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SBSarah G. Brooks
Sarah G. Brooks
RMRami H. Mahmoud
Rami H. Mahmoud
RLRachel Lin
Rachel Lin
Joachim FluhrJoachim Fluhr
Joachim Fluhr
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch

5 August 2024 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
LALuis Fernando Andrade
Luis Fernando Andrade
ZHZaim Haq
Zaim Haq
PAParsa Abdi
Parsa Abdi
SBSarah G. Brooks
Sarah G. Brooks
VVVeronica Voronina
Veronica Voronina
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch

28 October 2024 in Dermatitis®
Verified
Journal Article
Closed access
SBSarah G. Brooks
Sarah G. Brooks
LLLourdes M. Lopez
Lourdes M. Lopez
KMKayla D. Mashoudy
Kayla D. Mashoudy
GYGil Yosipovitch
Gil Yosipovitch
TCTali Czarnowicki
Tali Czarnowicki
Atopic dermatitis (AD) is a highly burdensome inflammatory skin condition affecting nearly one-quarter of the pediatric population and often continuing into adulthood. Despite recent advancements in systemic therapies providing temporary symptom relief over the past decade, AD frequently remains difficult to control, necessitating increased dosages or alternative treatments due to recurrent disease. This review synthesizes current literature to identify unmet needs of treating AD beyond medication-related limitations and evaluates existing therapies for their efficacy in modifying underlying disease mechanisms. Key findings include variability in AD pathophysiology and phenotypes across different age groups and ethnicities, indicating a need for research into endotype-specific treatments. The literature also comprises evidence suggesting that select current drugs, such as targeted biologics and Janus Kinase (JAK) inhibitors, may offer long-term disease-modifying benefits. Future management strategies should explore novel approaches, including manipulation of the microbiome, immune response, and neural function, as these may lead to additional improvements in AD treatment and long-term symptom relief.

13 March 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
HMHideki Mochizuki
Hideki Mochizuki
SBSarah G. Brooks
Sarah G. Brooks
RMRami H. Mahmoud
Rami H. Mahmoud
LALuis Fernando Andrade
Luis Fernando Andrade
JTJu Teresa
Ju Teresa
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch

21 January 2024 in JID Innovations
Verified
Journal Article
Open access
SBSarah G. Brooks
Sarah G. Brooks
RMRami H. Mahmoud
Rami H. Mahmoud
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch

16 July 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SBSarah G Brooks
Sarah G Brooks
LLLourdes M Lopez
Lourdes M Lopez
GEGeorge W Elgart
George W Elgart
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch
We describe an extensive, asymptomatic presentation of a rare condition in a 59-year-old male patient presenting with nonpruritic, nonpainful, hyperpigmented plaques on the upper body. Multiple treatments had failed to resolve the lesions, but with an added JAK inhibitor the patient developed no new lesions. We hope this description contributes to our limited understanding of this rarely reported clinical entity.